Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Diabetes Metab Res Rev. 2013 Jul;29(5):391-7. doi: 10.1002/dmrr.2405.
Metabolic syndrome is often beneficial from testosterone replacement therapy. Although testosterone and sex hormone-binding globulin (SHBG) are inversely associated with the risk of metabolic syndrome, it is controversial whether the association between testosterone and metabolic syndrome is independent of SHBG.
Testosterone, SHBG and metabolic syndrome were evaluated in 2361 men aged 20-73 years, who participated in the population-based Fangchenggang Area Male Health and Examination Survey. Total testosterone, SHBG and other biochemical profiles were measured. Free testosterone and bioavailable testosterone were calculated on the basis of Vermeulen's formula. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria for Asian population. The independent associations with metabolic syndrome were determined by multivariate logistic regression analysis.
Men with metabolic syndrome had a lower level of total testosterone, bioavailable testosterone, free testosterone, or SHBG than those without metabolic syndrome (all p < 0.001). Both total testosterone and SHBG were inversely correlated with body mass index or homeostasis model assessment of insulin resistance (all age-adjusted p < 0.001). Men within the lowest quartile of total testosterone [odds ratio (OR) = 4.86, 95% confidence interval (CI) = 2.72-8.68], bioavailable testosterone (OR = 3.04, 95% CI = 1.81-5.10), free testosterone (OR = 3.08, 95% CI = 1.81-5.27) or SHBG (OR = 4.28, 95% CI = 2.52-7.27) had a risk of metabolic syndrome after adjusting for age, smoking, homeostasis model assessment of insulin resistance and body mass index. Total testosterone remained inversely associated with metabolic syndrome after further adjusting for SHBG (OR = 0.95, 95% CI = 0.92-0.99), while SHBG remained inversely associated with metabolic syndrome after further adjusting for total testosterone (OR = 0.99, 95% CI = 0.97-1.00).
Total testosterone and SHBG are independent risk factors of metabolic syndrome. Prospective studies are needed to explore whether the association between sex hormones and metabolic syndrome was mediated by insulin resistance or obesity.
代谢综合征通常受益于睾丸激素替代疗法。尽管睾丸激素和性激素结合球蛋白(SHBG)与代谢综合征的风险呈负相关,但睾丸激素与代谢综合征之间的关联是否独立于 SHBG 仍存在争议。
对 2361 名年龄在 20-73 岁的男性进行了睾丸激素、SHBG 和代谢综合征评估,他们参加了基于人群的 Fangchenggang 地区男性健康和体检调查。测量了总睾丸激素、SHBG 和其他生化指标。根据 Vermeulen 公式计算游离睾丸激素和生物可利用的睾丸激素。根据亚洲人群的国家胆固醇教育计划成人治疗小组 III 标准定义代谢综合征。通过多变量逻辑回归分析确定与代谢综合征的独立关联。
患有代谢综合征的男性的总睾丸激素、生物可利用的睾丸激素、游离睾丸激素或 SHBG 水平低于没有代谢综合征的男性(均 P<0.001)。总睾丸激素和 SHBG 均与体重指数或胰岛素抵抗稳态模型评估呈负相关(所有年龄调整后 P<0.001)。总睾丸激素最低四分位数的男性[比值比(OR)=4.86,95%置信区间(CI)=2.72-8.68]、生物可利用的睾丸激素(OR=3.04,95%CI=1.81-5.10)、游离睾丸激素(OR=3.08,95%CI=1.81-5.27)或 SHBG(OR=4.28,95%CI=2.52-7.27)在调整年龄、吸烟、胰岛素抵抗稳态模型评估和体重指数后,代谢综合征的风险增加。在进一步调整 SHBG 后,总睾丸激素与代谢综合征仍然呈负相关(OR=0.95,95%CI=0.92-0.99),而在进一步调整总睾丸激素后,SHBG 与代谢综合征仍然呈负相关(OR=0.99,95%CI=0.97-1.00)。
总睾丸激素和 SHBG 是代谢综合征的独立危险因素。需要前瞻性研究来探讨性激素与代谢综合征之间的关联是否通过胰岛素抵抗或肥胖来介导。